Given previous evidence that HJURP promotes malignant progression and mediates cisplatin sensitivity via MYC in serous ovarian cancer, we focused on MYC for further investigation (Dou et al., 2022). The gene discussed is HJURP; the disease is ovarian serous adenocarcinoma.